Today: 21.Jun.2018

Robert Schenter, physicist: He specialized in the production of radioisotopes in reactors for nuclear medicine. Much of nuclear medicine depends on a steady supply of an isotope called molybdenum-99—“Mo-99” for short. A by-product of nuclear fission, Mo-99 decays to produce another radioactive substance, technetium-99m, which is employed in more than 16 million nuclear imaging procedures every year in the United States alone, including sentinel node biopsies in cancer surgery, bone scans, and cardiac stress tests.

World Nuclear News, Gene Cramer: Update on production of Molybdenum 99 in the United States. A license amendment request has been submitted to the US Nuclear Regulatory Commission to allow the University of Missouri Research Reactor to produce medical isotope molybdenum-99, partners MURR, Nordion and General Atomics announced yesterday. Once operational, production from MURR will be capable of meeting nearly half of US demand for the isotope, which is currently imported from outside North America. Nordion expects to start receiving Mo-99 from MURR in mid- to late-2018. Technetium-99m is a nuclear isomer of technetium-99. It is known as the most commonly used medical radioisotope because of its use in tens of millions of medical procedures annually.

Don Robertson is the retired Managing Director of NTP Radioisotopes SOC Ltd of South Africa. This article is very important because it gives a summary of the worldwide problems facing the production of the the radioisotope, Mo-99. This isotope is the workhorse of diagnostic nuclear medicine, used in approximately 80,000 Tc-99m scans per day. A variety of policies and regulations result in restricting full cost recovery for producers of this vital radioisotope. For all newsletters, see website: http://wci-ici.org/

Wendy Galbraith, University of Oklahoma College of Pharmacy - Nuclear Medicine Radionuclides Needed